SCM
BCAX

Sterling Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Sterling Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.9K Sell
1,000
-720
-42% -$12.4K ﹤0.01% 2031
2025
Q4 		$28.9K Sell
1,720
-506
-23% -$8.64K ﹤0.01% 2032
2025
Q3 		$35.1K Buy
2,226
+1,352
+155% +$15.1K ﹤0.01% 1892
2025
Q2 		$8.12K Buy
874
+712
+440% +$8.49K ﹤0.01% 2260
2025
Q1 		$2.11K Sell
162
-114
-41% -$1.51K ﹤0.01% 2574
2024
Q4 		$4.81K Buy
+276
New +$5.74K ﹤0.01% 2480

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Sterling Capital Management's BCAX Position: Q1 2026 in Review

Sterling Capital Management reduced its Bicara Therapeutics (BCAX) stake by 42% in Q1 2026, selling an estimated $12.4K and leaving 1,000 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2031.

Sterling Capital Management first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. The position peaked at $35.1K in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Sterling Capital Management held 1,000 shares of Bicara Therapeutics worth $19.9K as of Q1 2026.
  • Sterling Capital Management sold 720 Bicara Therapeutics shares in Q1 2026, an estimated $12.4K.
  • Bicara Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2031 holding.
  • Sterling Capital Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Sterling Capital Management's Bicara Therapeutics position peaked at $35.1K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.